Clinical Trials Sponsored by Altor BioScience

Total 2086 results

Altor BioScience

Completed

QUILT-1.004: A Single Center, Open-label, Pharmacokinetic Study of Subcutaneous ALT-803

Healthy

United States
Altor BioScience

Terminated

QUILT-3.002: ALT-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma

United States
Altor BioScience

Completed

Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies

Progressive Metastatic Malignancies

United States
Altor BioScience

Terminated

PK Sub-Study of QUILT-3.032 (CA ALT-803-01-16) and of QUILT-2.005 (CA ALT-803-01-14)

Pharmacokinetics

United States
Altor BioScience

Completed

QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel

Advanced Pancreatic Cancer

United States
Altor BioScience

Completed

A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors

Malignant Solid Tumour | Locally Advanced Malignant Neoplasm

United States
Altor BioScience
Genentech, Inc.; Tanox

Completed

Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome

Sepsis | Acute Respiratory Distress Syndrome | Acute Lung Injury

United States, Canada
Altor BioScience
National Cancer Institute (NCI)

Completed

A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
Altor BioScience
National Cancer Institute (NCI)

Completed

QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma

Metastatic Melanoma

United States
Altor BioScience
National Cancer Institute (NCI)

Unknown

A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

Transitional Cell Carcinoma of Bladder | Urethra Cancer | Ureter Cancer | Malignant Tumor of Renal Pelvis

United States
Altor BioScience
National Cancer Institute (NCI)

Unknown

QUILT-3.005: A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

United States
Altor BioScience
National Cancer Institute (NCI)

Terminated

QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

United States
Altor BioScience
M.D. Anderson Cancer Center

Withdrawn

ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
Medical University of South Carolina
Altor BioScience

Completed

ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
University of Arkansas
Bristol-Myers Squibb; Altor BioScience

Withdrawn

2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)

Multiple Myeloma

United States
Altor BioScience
James and Esther King Biomedical Research Program

Unknown

A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer

Non-muscle Invasive Bladder Cancer

United States
Altor BioScience
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome

Sepsis | Acute Respiratory Distress Syndrome | Acute Lung Injury

United States
Anwita Biosciences
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Phase 1 First-in-human Study of JS014

Lymphoma | Solid Tumor, Adult | Neoplasm Malignant | Neoplasm, Experimental

Taiwan
Dana-Farber Cancer Institute
Bristol-Myers Squibb; Altor BioScience; Miltenyi Biomedicine GmbH

Recruiting

CIML NK Cell in Head & Neck Cancer

Squamous Cell Carcinoma of the Head and Neck | Recurrent Head and Neck Squamous Cell Carcinoma

United States
Coherus Biosciences, Inc.
Shanghai Junshi Bioscience Co., Ltd.; Medpace, Inc.

Active, not recruiting

Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Hepatocellular Carcinoma | Non-Small Cell Lung Cancer | Advanced Solid Tumor

United States
Shanghai Junshi Bioscience Co., Ltd.
Iqvia Pty Ltd; TopAlliance Biosciences, Inc.

Active, not recruiting

Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

Advanced Malignancies

United States
Panolos Bioscience

Recruiting

Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent

Metastatic Colorectal Cancer | Hepatocellular Carcinoma | Gastric Cancer | Solid Tumor | Advanced Solid Tumor | Solid Tumor, Adult

Korea, Republic of
ExoRNA Bioscience

Recruiting

The Safety and Tolerability Study With ER2001 Intravenous Injection in Adults With Early Manifest Huntington's Disease

Huntington Disease

China
Ensol Bioscience

Completed

Study To Evaluate the Safety, Tolerability, and Pharmacokinetics After Subcutaneous Administration of C1K in Healthy Subjects

Healthy

Korea, Republic of
InFlectis BioScience

Active, not recruiting

Treatment Combining Riluzole and IFB-088 in Bulbar Amyotrophic Lateral Sclerosis (TRIALS Protocol)

Amyotrophic Lateral Sclerosis | ALS

France, Italy
Prolacta Bioscience

Completed

Safety Study of Human Milk Oligosaccharides in Healthy Adults

Healthy

United States
Prolacta Bioscience

Completed

Dietary Supplement With and Without a Probiotic and/or Antibiotic

Healthy Adults

United States
Dharma Bioscience

Active, not recruiting

Measuring Synovial Fluid Components

Knee Osteoarthritis

Argentina
YSOPIA Bioscience

Completed

Xla1 Christensenella Minuta, Phase I, Randomized, Partially Placebo-controlled Double-blind Protocol, Evaluating Safety, Tolerability and Impact on the Gut Microbiota in Healthy Volunteers, Overweight and Obese Adults (CAUSALITY)

Obesity | Metabolic Disease

United States
Donesta Bioscience

Completed

Effect of Food on the Bioavailability of 30 mg Estetrol (E4) Tablet in Healthy Postmenopausal Female Volunteers

Food-effect

Bulgaria
Implicit Bioscience

Withdrawn

IC14 in Adult Patients With Dengue Fever

Dengue Fever
Liventa Bioscience

Withdrawn

A Randomized Comparison of AmnioClear™ Human Allograft Amniotic Membrane vs. Moist Wound Dressing in the Treatment of Diabetic Wounds

Diabetic Foot Ulcers | Wound Care

United States
Pantarhei Bioscience

Completed

Preoperative Estetrol in Breast Cancer

Breast Cancer

Austria
Pantarhei Bioscience

Completed

Feasibility Study Into the Contraceptive Effect of Estetrol

Healthy

Netherlands
Cosmo Bioscience

Completed

Evaluation of Transgenic Lymphocyte Immunization Vaccine in Subjects With Prostate Adenocarcinoma

Prostatic Neoplasms

United States
NEXTGEN Bioscience

Not yet recruiting

Safety and Efficacy of Oral NXC-736 in Adult Participants With Severe Alopecia Areata

Alopecia Areata
Replicate Bioscience

Active, not recruiting

A Study of RBI-4000 in Healthy Participants

Healthy Volunteers

United States
Therasid Bioscience

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of TB-840 in Healthy Subjects

Healthy Volunteers

Korea, Republic of
Audubon Bioscience

Enrolling by invitation

AUD Biomarkers Study (Proteomic and Genomic Analysis of Biospecimens)

Cardiovascular Diseases | Autoimmune Diseases | Infectious Disease | Pregnancy Related | Hematologic Malignancy | Oncology | Renal Disease | Gastro-Intestinal Disorder | Genitourinary Disease

United States
NEXTGEN Bioscience

Completed

A First-in-Human Study to Assess Single and Multiple Doses of NXC736 in Healthy Participants

Healthy

Korea, Republic of
Prolacta Bioscience

Completed

Evaluation of Prolact-Plus Human Milk Fortifier

Infant, Very Low Birth Weight

United States
Implicit Bioscience

No longer available

Compassionate Use Open-Label Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19)

COVID | SARS-CoV2 | ARDS, Human | Ards

Italy
Prolacta Bioscience

Terminated

A Study of Safety of PBCLN-003 Following Antibiotic Therapy in Subjects With C.Difficile-associated Diarrhea

Clostridium Difficile Diarrhea

United States
Implicit Bioscience

Withdrawn

IC14 for Treatment of Amyotrophic Lateral Sclerosis

Motor Neuron Disease | Amyotrophic Lateral Sclerosis

Australia
Prolacta Bioscience

Completed

Randomized Study of Human-Milk Based Nutrition Versus Formula in Premature Infants

Infant, Very Low Birth Weight

United States, Austria
Apex Bioscience

Completed

Safety and Efficacy of PHP in the Treatment of Shock Associated With Systemic Inflammatory Response Syndrome (SIRS)

Systemic Inflammatory Response Syndrome | Shock
Implicit Bioscience

Recruiting

IC14 (Atibuclimab) in Arrhythmogenic Cardiomyopathy

Arrhythmogenic Right Ventricular Dysplasia | Arrhythmogenic Right Ventricular Cardiomyopathy 1 | Arrhythmogenic Left Ventricular Cardiomyopathy | Arrhythmogenic Cardiomyopathy

United States
Prolacta Bioscience

Recruiting

Study To Evaluate The Safety And Efficacy of PBCLN-010 In Combination With PBCLN-014 in Participants Receiving Allogeneic Hematopoietic Cell Transplantation

Hematologic Malignancy

United States
Hummingbird Bioscience

Recruiting

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Pancreatic Cancer | Non-Small Cell Lung Cancer | Metastatic Solid Tumor | Locally Advanced Solid Tumor

Australia
SN BioScience

Not yet recruiting

Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors

Breast Cancer | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Small-cell Lung Cancer | Pancreas Cancer

Korea, Republic of

Clinical Trials Sponsored by Altor BioScience

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Finland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations